Weber Kevin Daniel 4
4 · Biofrontera Inc. · Filed Mar 6, 2026
Research Summary
AI-generated summary of this filing
Biofrontera (BFRI) Director Kevin D. Weber Receives 20,000-Share Award
What Happened
- Kevin Daniel Weber, a director of Biofrontera Inc. (BFRI), received a derivative award on March 4, 2026 covering 20,000 shares. The Form 4 reports an acquisition price of $0.00 and a reported value of $0 for the award (derivative security).
Key Details
- Transaction date: 2026-03-04; Report filed: 2026-03-06.
- Reported terms: 20,000 derivative shares acquired @ $0.00; total reported value $0.
- Vesting: The award vests in twelve equal monthly installments beginning April 4, 2026 (Footnote F1).
- Notes: The filing states “options with different terms are not included” (Footnote F2).
- Shares owned after transaction: Not specified in the provided filing.
Context
- This was a grant/award of a derivative security (an option-type award per the footnote). Such awards are typically part of director compensation and are not the same as an open-market purchase or sale. The filing does not indicate any immediate sale or cashless exercise.
Insider Transaction Report
Form 4
Biofrontera Inc.BFRI
Weber Kevin Daniel
Director
Transactions
- Award
Employee stock option (right to buy)
[F1][F2]2026-03-04+20,000→ 20,000 totalExercise: $0.90Exp: 2036-03-04→ Common Stock (20,000 underlying)
Footnotes (2)
- [F1]The option vests in twelve equal monthly installments beginning on April 4, 2026.
- [F2]Options with different terms are not included.
Signature
/s/ Daniel Hakansson, Attorney-in-fact for Kevin D. Weber|2026-03-06